1. Introduction {#s0005}
===============

Circadian rhythm and habitual sleep disturbances are common features of Huntington's disease (HD) that occur early in the disease course and exacerbate impairments in cognitive function, metabolism, hormone regulation, mood and quality of life ([@bib4], [@bib9], [@bib30], [@bib35]).

A number of studies have reported dysregulation of markers of circadian rhythm and habitual sleep-wake outcomes in individuals with HD. In particular, increased morning cortisol output has been reported in individuals with premanifest HD ([@bib23], [@bib46]). Reduced mean and acrophase concentrations and a temporal spread of melatonin release, indicating a potential phase shift in melatonin, have been reported in individuals with premanifest HD ([@bib26]). Furthermore, studies have reported disruption of the sleep-wake cycle and delayed sleep phase in individuals with HD ([@bib4], [@bib35]). Despite these findings, the neurobiological origin of circadian rhythm and habitual sleep-wake disturbances in individuals with HD has been poorly investigated and warrants further exploration.

Pathological changes within the hypothalamus have been proposed to disrupt circadian rhythm and sleep in individuals with HD ([@bib4], [@bib35]). Hypothalamic nuclei, particularly the suprachiasmatic nucleus, are known to be integrally involved in the regulation of circadian markers such cortisol and melatonin, as well as sleep ([@bib41], [@bib44]). Studies have reported grey matter volume loss and microglial activation within the hypothalamus and circadian rhythm and sleep disturbances that arise concomitantly in individuals with premanifest HD ([@bib30], [@bib35], [@bib39], [@bib43]). Despite these findings, only one study has examined the potential link between neural pathology and circadian rhythm and sleep disturbances in individuals with HD ([@bib6]). [@bib6] reported an association between subjective sleep disturbances and neural pathology in HD. However, the authors did not use formalised sleep questionnaires to examine sleep and did not evaluate markers of circadian rhythm relative to neural pathology. There is, therefore, a need for subsequent research to investigate more closely the potential relationships between hypothalamic pathology and circadian rhythm and sleep disturbances in HD.

The purpose of this study was to evaluate whether hypothalamic pathology is associated with the dysregulation of biological and clinical markers of circadian rhythm, particularly cortisol, melatonin and sleep-wake timing, and habitual sleep in individuals with premanifest HD. We hypothesized that hypothalamic pathology would be associated with dysregulation of circadian rhythm and habitual sleep, as evidenced by significant alterations in cortisol and melatonin release and habitual sleep-wake cycles in individuals with premanifest HD.

2. Materials and methods {#s0010}
========================

2.1. Participants {#s0015}
-----------------

Thirty-five premanifest HD individuals and 31 age- and gender-matched healthy controls were recruited from existing databases, HD clinics and media advertisements in Perth and Melbourne. Inclusion criteria for premanifest HD individuals were a cytosine-adenine-guanine (CAG) repeat length ≥ 40 and a diagnostic confidence score \< 2 on the Unified Huntington's Disease Rating Scale Total Motor Score (UHDRS-TMS) ([@bib40]). Exclusion criteria for all participants were, presence of known musculoskeletal, metabolic, endocrine, cardiovascular or sleep disorders, recent or long-standing substance abuse, shift work other neurological conditions and, for healthy controls, a family history of HD. Five participants withdrew from the study or contributed incomplete data and were excluded from analyses, leading to a total of 32 premanifest HD and 29 healthy individuals.

All aspects of the study were conducted in accordance with the Declaration of Helsinki. Ethical approval was granted by the Edith Cowan University and Monash University Human Research Ethics Committees. All participants provided written informed consent.

2.2. Study procedures {#s0020}
---------------------

Testing procedures included 3T MRI scans for hypothalamic imaging, saliva sampling to quantify morning cortisol and evening melatonin, wrist-worn actigraphy for monitoring sleep, a sleep diary for monitoring habitual sleep patterns and questionnaires for monitoring sleep quality, psychological stress, physical activity, anxiety and depression.

2.3. Acquisition and pre-processing of MRI data {#s0025}
-----------------------------------------------

T1-weighted structural images of the brain were obtained from each participant in Perth or Melbourne using a GE Healthcare Discovery and a Siemens Skyra 3T MRI scanner, respectively. In Perth, images were acquired with a 24-channel head coil using an IR-SPGR sequence (TA = 9 m 59 s, TR = 3 s, TE = Min, TI = 400 ms, flip angle = 11°, field of view = 256 mm, image matrix = 256 × 256, 1 mm^3^ isotropic voxels). In Melbourne, acquisition took place with a 32-channel head coil and an MP-RAGE sequence (TA = 9 m 14 s, TR = 2.3 s, TE = 2.96 ms, TI = 900 ms, flip angle = 9°, field of view = 256 mm, image matrix = 256 × 256). Images were acquired consistently across both sites according to the Alzheimer's Disease Neuroimaging Initiative protocols for multi-site imaging ([@bib24]). Pre-processing of images was conducted according to the SPM12 pipeline ([Supplementary data](#s0165){ref-type="sec"}).

2.4. Measurement of biological markers of circadian rhythm {#s0030}
----------------------------------------------------------

Salivary cortisol and melatonin have previously been shown to be useful measures of circadian rhythm ([@bib15], [@bib48]). Participants were given written and verbal instructions to collect saliva samples by passive drool into polypropylene collection tubes (SSI Bio) at the same time on two consecutive days for determination of morning cortisol and evening melatonin concentrations. Participants collected saliva samples at four time points in the morning (15, 30, 45 and 60 min following awakening) for morning cortisol analysis and four time points in the evening at one hour intervals from two hours before their usual bedtime (T1) until one hour after their usual bedtime (T4) for melatonin analysis. Saliva samples were collected according to criteria from previous studies ([@bib46], [@bib48]) to avoid contamination of samples (see [Supplementary files](#s0165){ref-type="sec"}). Based on these criteria, a questionnaire was devised to monitor participant compliance. Saliva samples were stored at −80 °C until analysis using commercially available salivary cortisol and melatonin ELISA kits (Salimetrics, USA) according to the manufacturer's instructions.

2.5. Measures of habitual sleep-wake parameters {#s0035}
-----------------------------------------------

### 2.5.1. Actigraphy {#s0040}

At the commencement of the study, a convenience sample of individuals with premanifest HD and healthy controls were given the opportunity to undertake habitual sleep monitoring using actigraphy. Of the original cohort, 19 premanifest HD and 24 healthy individuals underwent home-based actigraphy sleep measurement for seven consecutive nights to assess habitual sleep-wake patterns. Actigraphy was recorded at 30 Hz using wrist-worn GT3X+ ActiGraph monitors (ActiGraph, USA) on the non-dominant wrist. The start and end time of sleep periods were recorded using the Consensus Sleep Diary ([@bib11]).

Wrist-based actigraphy has been used previously to assess circadian rhythm via analysis of habitual sleep-wake patterns in individuals with HD and in other populations ([@bib2], [@bib35]). Therefore, here we similarly used ActiGraph monitors, which were initialised, downloaded and analysed using the ActiLife software (version 6.8). Data were scored with a low frequency extension filter in 60 s epochs as awake or sleep according to the Cole-Kripke algorithm ([@bib13]). Total sleep time, sleep onset latency, wake after sleep onset, number of awakenings and sleep efficiency outcomes were calculated for each night and then averaged across the seven nights to obtain single values for use in subsequent analyses.

### 2.5.2. Consensus sleep diary {#s0045}

Habitual sleep-wake timing was evaluated using the Consensus Sleep Diary ([@bib11]). Participants were required to document time in bed, time of awakening, time to sleep onset, number of awakenings and sleep quality for seven nights in combination with actigraphy assessment.

### 2.5.3. Subjective sleep quality and daytime somnolence {#s0050}

Sleep quality was assessed in all participants using the Pittsburgh Sleep Quality Index (PSQI) ([@bib10]). Daytime somnolence was measured using the Epworth Sleepiness Scale (ESS) ([@bib25]).

2.6. Stress, anxiety and depression symptomatology {#s0055}
--------------------------------------------------

The Perceived Stress Scale ([@bib12]) was used to measure psychological stress in the previous month. The Perceived Stress Scale has been demonstrated to be a valid measure of perceived psychological stress in individuals with HD ([@bib17]). Symptoms of anxiety and depression were measured using the Hospital Anxiety and Depression Scale (HADS). This scale has been previously demonstrated to be valid and reliable in HD ([@bib14]).

2.7. Physical activity {#s0060}
----------------------

Physical activity levels were recorded prior to and during saliva sampling days using the Minnesota Leisure Time Physical Activity Questionnaire. Metabolic equivalents (METs) were calculated using recorded physical activity levels, the Compendium of Physical Activities database and estimated resting metabolic rate (RMR) ([@bib1]). RMR was calculated using the Harris-Benedict formula (see [Supplementary file](#s0165){ref-type="sec"}) ([@bib21]).

2.8. Statistical analysis {#s0065}
-------------------------

### 2.8.1. Hypothalamic volume {#s0070}

A hypothalamus mask from the WFU Pick Atlas (http://fmri.wfubmc.edu/software/pickatlas), dilated by 3 mm, was used to restrict analysis to this area ([@bib8]). Grey matter images from individuals with premanifest HD and healthy controls were compared voxel-wise using a two-sample t-test to evaluate group differences in the hypothalamus. Gender, site and age were included as covariates of no interest. Next, we investigated group differences in the association between hypothalamic volume and cortisol and/or melatonin output in individuals with premanifest HD compared to healthy controls, using a categorical by continuous covariate interaction model. The model included group regressors, one for each group, and regressors modelling change in cortisol or melatonin output, one for each group. The following contrasts were used to model the group by cortisol/melatonin output interaction effect: \[0 0 1 −1\] and \[0 0 −1 1\]. Gender, site, age, PSS, ESS, and PSQI were included as covariates of no interest. In premanifest HD, we adjusted also for CAP score.

We also evaluated the relationship between hypothalamic volume and disease status (i.e. CAP score). Given the exploratory nature of this study and our *a priori* interest in the hypothalamus, the threshold for statistical significance for all analyses was set at *α* = 0.05.

### 2.8.2. Salivary cortisol and melatonin {#s0075}

Missing data points from saliva sampling (removed due to suspected blood contamination) were imputed by calculating the average of the participant's previous and subsequent values in the curve (n= 2 of 504, 0.40%), unless the missing value was the first time point in each curve (n= 3 of 504, 0.60%), in which case the group average was imputed to avoid removing the participant from analyses and maintain sample size ([@bib46]). Area under the curve with respect to ground (AUC~*G*~) was calculated using the trapezoid rule for morning cortisol and evening melatonin output on the two consecutive days ([@bib16], [@bib46]).

Normality assumptions for all variables were tested using a Shapiro-Wilk test. Between-group differences were examined using a t-test for continuous variables and a two sample proportion test for categorical variables. Spearman correlation coefficient was calculated to assess relationships between cortisol AUC~*G*~, melatonin AUC~*G*~ and Perceived Stress Scale, PSQI and Consensus Sleep Diary scores. Statistical significance was set at p ≤ 0.05. Statistical analyses were performed using STATA version 9.1.

3. Results {#s0080}
==========

3.1. Participant demographics and clinical characteristics {#s0085}
----------------------------------------------------------

There were no significant differences for age or gender between premanifest HD patients and healthy controls (*p* = 0.472 and 0.283, respectively; [Table 1](#t0005){ref-type="table"}).Table 1Demographic and clinical characteristics of premanifest Huntington\'s disease and healthy control participants.Table 1**Premanifest HD (n=32)Healthy Controls (n=29)*****p*****-valueDemographic Characteristics**Age, mean ± SD44.5 ± 11.444.3 ± 10.80.472Male, n (%)11 (34.4)8 (27.6)0.283  **Clinical Characteristics**CAGn, mean ± SD42.8 ± 2.8N/AN/AEstimated age of onset, median (IQR)47.4 (44.9--55.7)N/AN/ADiagnostic Confidence Level, mean ± SD0.38 ± 0.70N/AN/AUHDRS-TMS, mean ± SD4.35 ± 7.24N/AN/ADisease burden score, mean ± SD305.0 ± 76.8N/AN/ACAPs, mean ± SD0.89 ± 0.18N/AN/ABMI, mean ± SD26.47 ± 4.526.75 ± 5.90.417Smoker, n (%)6 (18.8)0 (0.0)0.007[\*](#tbl1fnStar){ref-type="table-fn"}High alcohol consumption, n (%)[\*\*](#tbl1fnStarStar){ref-type="table-fn"}5 (15.6)6 (20.7)0.303Psychotropic medication, n (%)3 (9.4)5 (17.2)0.181Monthly METs, mean ± SD3278.0 ± 6272.57481.2 ± 9584.50.022[\*](#tbl1fnStar){ref-type="table-fn"}METs (previous day), mean ± SD168 ± 359.285.1 ± 211.80.141[^2][^3][^4][^5]

3.2. Hypothalamic volume {#s0090}
------------------------

A significant decrease in grey matter volume in the anterior-superior region of the left side of the hypothalamus was observed in individuals with premanifest HD compared to healthy controls (peak voxel at MNI -9 1 -4; *t* = 2.38; *k* = 22; see [Fig. 1](#f0005){ref-type="fig"}A). We also found a significant negative association in premanifest HD between grey matter volume bilaterally in the anterior-superior and anterior-inferior regions of the hypothalamus and CAP score (*r* = -0.42; see [Table 3](#t0015){ref-type="table"} and [Fig. 1](#f0005){ref-type="fig"}B).Fig. 1Results from voxel-based morphometry analyses showing overlap between maps of (A) the hypothalamic volume group difference, (B) association between hypothalamus loss and CAPs in premanifest HD, (C) group by cortisol output interaction and (D) group by melatonin output interaction. (E) shows the map of group by cortisol output interaction effect on hypothalamic volume (as per voxel-wise analysis) and a scatterplot illustrating the interaction and (F) shows the map of group by melatonin output interaction effect on hypothalamic grey matter volume and scatterplot illustrating the interaction. The data points in the scatterplot correspond to the average intensity across all voxels within the area exhibiting a significant interaction effect for each participant. Slice labels are displayed on top. Cross-slices are shown. Crosshairs in (A), (B), (C), and (D) are centred at MNI -9 1 -5. L= left; R= right.Fig. 1

3.3. Biological markers of circadian rhythm {#s0095}
-------------------------------------------

No significant differences were observed between individuals with premanifest HD and healthy control participants in the amplitude of morning cortisol or evening melatonin output at any of the time points sampled (*p* \> 0.05; [Table 2](#t0010){ref-type="table"}). Furthermore, no differences were observed in total morning cortisol (*p* = 0.357) or evening melatonin (*p* = 0.219) output when subject to area under the curve analysis with respect to ground (AUC~*G*~; [Table 2](#t0010){ref-type="table"}).Table 2Cortisol and melatonin values, subjective and objective sleep outcomes and stress, anxiety and depression questionnaire scores for premanifest Huntington\'s disease and healthy control participants.Table 2**Premanifest HDHealthy Controls*****p*****-valueCortisol nmol/L (mean ± SD)**Time of awakening (hh:mm)6:06 ± 1:016:21 ± 0:450.141        Time of sample relative to awakening:+15 min11.08 ± 4.4011.28 ± 3.320.421+30 min13.84 ± 4.5913.42 ± 4.290.357+45 min13.69 ± 3.5613.30 ± 4.410.352+60 min12.26 ± 3.4711.62 ± 3.720.244AUC~*G*~38.17 ± 11.3039.20 ± 10.610.357  **Melatonin (pg/mL)**Reported usual bedtime (hh:mm)22:05 ± 0:5022:10 ± 0:310.322        Time of sample relative to bedtime:-2 h10.87 ± 7.6810.02 ± 6.190.319-1 h12.16 ± 7.0713.71 ± 7.840.210+0 h17.10 ± 9.3019.44 ± 11.100.187+1 h19.42 ± 12.0222.07 ± 11.110.188AUC~*G*~49.20 ± 25.8844.41 ± 21.770.219        Actigraphy measures:Total time in bed (min)464.28 ± 46.73458.58 ± 43.100.680Total sleep time (min)403.17 ± 45.20415.12 ± 40.250.365Sleep onset latency (min)7.10 ± 6.804.39 ± 3.770.106Wake after sleep onset (min)54.02 ± 25.9739.07 ± 16.870.028[\*](#tbl2fnStar){ref-type="table-fn"}Number of awakenings18.47 ± 6.7214.55 ± 5.330.039[\*](#tbl2fnStar){ref-type="table-fn"}Average duration of awakenings (min)2.87 ± 0.642.75 ± 0.870.625Sleep efficiency (%)86.98 ± 5.4290.68 ± 3.750.012[\*](#tbl2fnStar){ref-type="table-fn"}PSQI global score5.76 ± 3.024.97 ± 2.440.134Epworth Sleepiness Scale Score4.69 ± 3.616.76 ± 3.370.025[\*](#tbl2fnStar){ref-type="table-fn"}        Consensus Sleep Diary:Total time in bed (min)430.42 ± 61.33434.84 ± 68.480.372Total sleep time (min)385.82 ± 53.90387.92 ± 74.770.453Sleep onset latency (min)16.65 ± 19.9014.35 ± 13.920.303Wake after sleep onset (min)19.04 ± 25.3716.93 ± 22.890.412Sleep efficiency90.52 ± 5.1789.32 ± 9.960.487Number of awakenings1.25 ± 1.471.75 ± 1.030.057Average duration of awakenings (min)10.18 ± 23.468.97 ± 11.110.059Restorative quality of sleep3.75 ± 0.813.80 ± 0.920.411Perceived Stress Scale17.12 ± 6.7219.86 ± 6.850.062        HADS:Total score7.54 ± 5.308.38 ± 5.690.276Anxiety5.06 ± 3.486.00 ± 3.970.164Depression2.49 ± 2.522.38 ± 2.140.427[^6][^7][^8]

3.4. Habitual sleep outcomes {#s0100}
----------------------------

### 3.4.1. Actigraphy {#s0105}

Premanifest HD individuals exhibited a decreased sleep efficiency compared to healthy controls (*p* = 0.012). A significant increase in the number of awakenings (*p* = 0.039) and time spent awake after sleep onset (*p* = 0.028) were also observed in premanifest HD participants compared to healthy controls ([Table 2](#t0010){ref-type="table"}).

### 3.4.2. Consensus sleep diary {#s0110}

No significant differences were observed in self-report sleep outcomes using the Consensus Sleep Diary ([Table 2](#t0010){ref-type="table"}).

### 3.4.3. Subjective sleep outcomes {#s0115}

There were no significant differences between premanifest HD individuals and healthy controls in global PSQI score (*p* = 0.134). The average PSQI score in the premanifest HD group fell above the cut-off of 5, suggesting a disruption in sleep quality. Although healthy controls scored significantly higher than premanifest HD individuals on the ESS, scores for both groups remained within the normative range (\< 10) ([@bib25]).

3.5. Stress, anxiety and depression questionnaires {#s0120}
--------------------------------------------------

No significant differences were observed in stress (*p* = 0.062), anxiety (*p* = 0.164) or depression (*p* = 0.427) symptomatology between premanifest HD and healthy individuals ([Table 2](#t0010){ref-type="table"}). Furthermore, values on the Perceived Stress Scale and HADS were considered below threshold, indicating no clinically meaningful stress, anxiety or depressive symptomatology in the premanifest HD and healthy control groups.

3.6. Physical activity {#s0125}
----------------------

The premanifest HD group reported significantly less monthly physical activity (METs) than healthy controls (*p* = 0.022; [Table 1](#t0005){ref-type="table"}). Physical activity on the day prior to saliva sampling did not differ between the groups, negating any acute effects of physical activity on hormone levels. Furthermore, there was no association between reported physical activity levels and measures of sleep, cortisol and melatonin output and hypothalamic volume.

3.7. Associations between hypothalamic volume and circadian markers {#s0130}
-------------------------------------------------------------------

A significant negative association was revealed by voxel-wise analysis between grey matter volume in the left hypothalamus and morning cortisol output in the premanifest HD group. This association was found to be moderate (*r* = -0.39), indicating that lesser grey matter volume in the left side of the hypothalamus is associated with greater morning cortisol output. No significant association was observed in the healthy control group ([Fig. 1](#f0005){ref-type="fig"}E and [Table 3](#t0015){ref-type="table"}). This group difference in the association between hypothalamic volume and morning cortisol output was statistically significant, as shown by interaction analysis ([Fig. 1](#f0005){ref-type="fig"}C, [Fig. 1](#f0005){ref-type="fig"}E and [Table 3](#t0015){ref-type="table"}). The group by cortisol output interaction encompassed two separate areas -- first, the region spanning the posterior hypothalamus and the superior tuberal hypothalamus and second, the anterior-inferior hypothalamic region.Table 3Association analyses between hypothalamic volume and CAPs, cortisol and melatonin.Table 3**Side*****k*****Peak voxel*****t*****scoreMNI coordinatesCAPs**Negative association with CAPs in premanifest HDB2043.16-3 2 -7  **Cortisol**Negative association with cortisol output in premanifest HDL1612.54-10 1 -4Group by cortisol output interactionL1862.32-10 1 -4  **Melatonin**Positive association with melatonin output in healthy controlsL1612.67-10 1 -6Group by melatonin output interactionL2012.41-6 2 -8[^9][^10][^11]

A negative relationship between grey matter volume in the right side of the hypothalamus and morning cortisol output was seen in healthy controls, but not in premanifest HD participants, and the group by cortisol output interaction was significant ([Table 3](#t0015){ref-type="table"}). However, the association between right hypothalamic grey matter volume and morning cortisol output in healthy controls was weak (*r* = -0.06), indicating a non-existent relationship in this case.

Grey matter volume in the left side of the hypothalamus was positively associated with evening melatonin output in healthy controls (*r* = 0.36), but not in premanifest HD individuals ([Fig. 1](#f0005){ref-type="fig"}F and [Table 3](#t0015){ref-type="table"}). This group difference in the correlation between hypothalamic volume and evening melatonin output was statistically significant ([Fig. 1](#f0005){ref-type="fig"}D, [Fig. 1](#f0005){ref-type="fig"}F and [Table 3](#t0015){ref-type="table"}). The group by melatonin output interaction encompassed the region extending from the superior tuberal hypothalamus to the anterior-inferior hypothalamus.

3.8. Associations between hypothalamic volume and habitual sleep outcomes {#s0135}
-------------------------------------------------------------------------

No reliable pattern of associations was observed between hypothalamic volume and measures of subjective sleep quality, sleep onset latency, number of awakenings, sleep efficiency or perceived stress in the premanifest HD or healthy cohorts.

4. Discussion {#s0140}
=============

Hypothalamic pathology and disturbances in circadian rhythm and sleep arise during the premanifest stages of HD. Despite the central role of the hypothalamus in mediating the circadian rhythm and sleep-wake timing, only one study has attempted to discern the possible relationship between hypothalamic pathology and sleep disturbances in individuals with HD ([@bib6]). In the absence of robust data, the aim of this study was to examine the potential relationship between hypothalamic pathology and circadian rhythm and habitual sleep outcomes in individuals with premanifest HD.

Consistent with previous findings ([@bib43]), significantly reduced grey matter volume was observed in the hypothalamus of individuals with premanifest HD compared to healthy controls. Using normative parcellations of the hypothalamus that rely on visible anatomic landmarks in MR images ([@bib32]), this reduced grey matter volume can be located to the anterior-superior region of the hypothalamus, a region comprising the paraventricular nucleus (PVN), which mediates the release of cortisol and melatonin. Reduced hypothalamic volume was found to be associated with CAP score, suggesting a relationship between estimated time to disease onset and loss of hypothalamic grey matter volume. Interestingly, degeneration within the hypothalamus was leftward biased. The reason for this is unknown. Studies have reported a leftward-biased pattern of grey matter atrophy in the striatum in individuals with manifest HD ([@bib33], [@bib36]), however, this has not been reported in the striatum or the hypothalamus in individuals with premanifest HD. [@bib33] postulated that the earliest pathological changes in the hypothalamus occur on the left side and become more apparent as individuals approach clinical onset, however additional research is needed to support this supposition.

The pathological mechanisms responsible for reduced hypothalamic volume in individuals with HD are not yet understood. Evidence from post-mortem investigations and studies in mouse models provides insight into potential mechanisms by which hypothalamic changes could occur, as well as mechanisms by which these changes could impact on circadian rhythm and habitual sleep outcomes. For example, neuronal inclusions of mutant huntingtin in suprachiasmatic nucleus (SCN) tissue at post-mortem ([@bib5]), may directly mediate changes in the functioning of the SCN. Such neuronal inclusions of mutant huntingtin within the SCN could reduce the number of vasoactive intestinal polypeptide and arginine vasopressin expressing neurons, which are crucial in the regulation of SCN activity ([@bib3], [@bib22]), as well as post-transcriptional changes in these neuropeptides, which have been reported in HD ([@bib47]). These changes, together with a loss of orexin-releasing neurons in the lateral hypothalamus which has been reported in individuals with HD at post-mortem and in mouse models of HD ([@bib5], [@bib37]), could result in impaired functioning of the hypothalamic nuclei and lead to the disruption of the circadian rhythm and sleep-wake cycle that has been reported in individuals with HD and in HD mouse models ([@bib28], [@bib31], [@bib34], [@bib35]). These potential mechanisms are complex and interrelated and require further investigation.

The reduction in hypothalamic grey matter volume in individuals with premanifest HD was significantly associated with morning cortisol release. This relationship was not observed in healthy controls. Conversely, the association between hypothalamic volume and evening melatonin concentrations observed in healthy controls was absent in individuals with premanifest HD. Both the group by cortisol output and the group by melatonin output interaction effect on hypothalamic grey matter volume occurred across regions encompassing the SCN and the PVN. Despite significantly reduced habitual sleep efficiency and an increase in the number of awakenings and time spent awake after sleep onset in individuals with premanifest HD, which aligns with previous reports of sleep disturbances in premanifest HD ([@bib30]), hypothalamic volume was not significantly associated with habitual sleep outcomes. The lack of consistent associations between hypothalamic volume and habitual sleep outcomes was unexpected, especially considering the known role of the hypothalamus in regulating the sleep-wake cycle via the SCN and its connections with the ventrolateral preoptic nucleus and the lateral area within the hypothalamus ([@bib7], [@bib41]).

While inconsistent relationships were observed between hypothalamic volume and habitual sleep outcomes, further studies should assess the impact of reduced hypothalamic volume on changes in the underlying sleep electroencephalogram, which is reported to be altered in HD mouse models and in individuals with HD ([@bib18], [@bib19], [@bib27], [@bib30], [@bib38]). Such analyses would allow further characterisation of the impact of hypothalamic changes on sleep outcomes in HD.

Despite observing differences in the relationships between hypothalamic grey matter volume and cortisol and melatonin in the premanifest HD cohort compared to healthy controls, no differences in morning cortisol or evening melatonin release were observed between the two groups, which is contradictory to previous reports ([@bib26], [@bib46]). It is important to note that a large proportion of our premanifest HD cohort were females (65.6%). This is of relevance as sex-specific differences in circadian rhythm dysfunction have been reported in HD mouse models ([@bib29]). In particular, female HD mice exhibit less severe or delayed changes in activity levels and behavioural fragmentation compared to male HD mice ([@bib29]). Therefore, the lack of differences in cortisol and melatonin release between individuals with premanifest HD and healthy controls may be related to sex-specific effects.

Conceivably, the right side of the hypothalamus, or indeed other structures involved in the release of cortisol and melatonin, such as the pituitary or pineal glands, may be able to compensate for the reduced hypothalamic volume during the premanifest stages of the disease and thereby maintain normal regulation of cortisol and melatonin release. This is supported by emerging evidence indicating the presence of compensatory neural functions in individuals with HD ([@bib20], [@bib42]). This theory nevertheless requires further validation in larger longitudinal studies.

This study is not without limitations. Firstly, current imaging methods are not yet sensitive enough to capture the individual nuclei within the hypothalamus; however, parcellation approaches that rely on anatomic landmarks visible on MR images (e.g. [@bib32]) allow the distinction of the different hypothalamic regions, which affords some insight into which structures may be affected. Secondly, this study evaluated cortisol and melatonin regulation using saliva sampling, which is known to be more variable than blood sampling. However, salivary cortisol and melatonin sampling was preferred to blood sampling as previous studies indicate that blood sampling elevates cortisol levels ([@bib49]). Thirdly, this study included a large proportion of females with HD, which may have influenced our ability to find significant differences in cortisol/melatonin release between individuals with premanifest HD and healthy controls. Discrepancies in cortisol and melatonin findings between this study and others may also reflect differences in measurement protocols (i.e., frequency of sampling time points), patient characteristics or seasonal differences ([@bib26], [@bib45], [@bib46]). A lack of concordance also existed between the habitual sleep measures, potentially due to differences in reporting methods (i.e. subjective versus objective). No evidence of elevated stress, anxiety or depression was noted, indicating that mood disorders did not impact on markers of circadian rhythm or habitual sleep. Future studies should assess the relationship between hypothalamic pathology and sleep architecture in individuals with premanifest HD using polysomnography.

In summary, our findings show that individuals with premanifest HD exhibit leftward biased hypothalamic pathology that is differentially associated with markers of circadian rhythm, but not consistently associated with habitual sleep-wake deficits, when compared to healthy controls. However, the lack of differences in concentrations of markers of circadian rhythm between the two groups suggests the possibility of neural compensation, facilitated by the right hemisphere of the hypothalamus or by other brain structures involved in the circadian and sleep cycles, as a mechanism involved in maintaining the regulation of the circadian rhythm and habitual sleep-wake function in individuals with premanifest HD. Larger, longitudinal studies are required to further investigate the role of hypothalamic pathology in circadian rhythm and habitual sleep-wake disturbances in HD as the disease course lengthens.
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[^7]: HD= Huntington\'s disease; AUC~*G*~= area under the curve with respect to ground; PSQI= Pittsburgh Sleep Quality Index; HADS= Hospital Anxiety and Depression Scale.

[^8]: Results are significant at *p* \< 0.05.

[^9]: Group differences were analysed using two-sample t-tests.

[^10]: \*Results are significant at *p* \< 0.05, uncorrected.

[^11]: *k* = No. of voxels; MNI = Montreal Neurological Institute; HD = Huntington\'s disease; B = bilateral; L = left.
